Clinical Trials
12 trialsNCT04768881 2024-08-23
Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
Karyopharm Therapeutics Inc
Phase 2 Terminated
NCT04854434 2023-11-03
A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations
Karyopharm Therapeutics Inc
Phase 2 Terminated
NCT04843579 2023-10-25
ClaSPd
Weill Medical College of Cornell University
Phase 2 Terminated
NCT03193437 2023-02-16
SELECT
Georgetown University
Phase 2 Terminated
NCT01986348 2023-01-26
KING
Karyopharm Therapeutics Inc
Phase 2 Terminated
NCT02138786 2023-01-26
SIRRT
Karyopharm Therapeutics Inc
Phase 2 Terminated
NCT02146833 2023-01-26
SHIP
Karyopharm Therapeutics Inc
Phase 2 Terminated
NCT02213133 2023-01-26
STARRS
Karyopharm Therapeutics Inc
Phase 2 Terminated
NCT02314247 2023-01-26
Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma
Karyopharm Therapeutics Inc
Phase 2 Terminated
NCT03071276 2020-05-22
Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT02215161 2018-06-26
Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer
University of California, San Francisco
Phase 2 Terminated
NCT02351505 2016-05-16
Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Terminated